What is it about?
Monocyte-to-lymphocyte ratio can predict sorafenib response and a high MLR is correlated with poor prognosis in patients with advanced hepatocellular carcinoma.
Featured Image
Why is it important?
Our findings showed that patients with MLR>0.35 had significantly shorter OS and PFS than those with MLR ≤0.35. Thus, MLR and AST have considerable potential as stratification factors in patients with hepatocellular carcinoma who are receiving sorafenib treatment.
Perspectives
This article may contribute to the individualized treatment of sorefenib.
Zhenfeng Zhu
Fudan University
Read the Original
This page is a summary of: Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma, OncoTargets and Therapy, October 2018, Dove Medical Press,
DOI: 10.2147/ott.s173275.
You can read the full text:
Resources
Contributors
The following have contributed to this page
